Neoantigen Cancer Vaccine Platform
Oncology
ResearchActive
Key Facts
About Orlance
Orlance is advancing the MACH-1 platform, a needle-free gene gun technology that delivers powdered DNA or RNA vaccines directly into the epidermis, aiming to reduce doses by up to 90% and eliminate cold chain requirements. The company has secured significant non-dilutive funding, primarily from NIH SBIR grants totaling over $16.8M, to progress its pipeline toward Phase 1 trials. With a lead universal flu vaccine at the pre-IND stage, Orlance is preparing for a $12M Series A round in 2026 and is actively seeking development partners to expand its portfolio of vaccine and immunotherapy assets.
View full company profileTherapeutic Areas
Other Oncology Drugs
| Drug | Company | Phase |
|---|---|---|
| Bi-XDC with PROTACs | Coherent Biopharma | IND-enabling |
| Bi-XDC with RPT | Coherent Biopharma | Early-stage |
| mRNA Anticancer Vaccine | Sunshine Biopharma | Preclinical Research |
| Biosimilar Bevacizumab | Organon (2) | Phase 3 |
| Biosimilar Pembrolizumab | Organon (2) | Phase 3 |
| BCL-2 Inhibitor Program | Vincerx Pharma | Preclinical |
| Not specified in provided content | 3Sbio | Various |
| Preclinical Projects | Zion Pharma | Preclinical |
| Attenukine Oncology Candidate | Teva | Phase 1 |
| XEMA Tumor Marker ELISA Kit | XEMA Group | Commercial |
| KRAS inhibitor | Risen Pharma Tech | Preclinical/Phase 1 |
| KEAP1 Activator Program | Vividion Therapeutics | Phase 1 |